Literature DB >> 28735800

Durability of Hemiarthroplasty for Pathologic Proximal Femur Fractures.

Matthew T Houdek1, Cody C Wyles1, Joshua R Labott2, Peter S Rose1, Michael J Taunton1, Franklin H Sim1.   

Abstract

BACKGROUND: The hip is a common location for metastatic tumors. Due to the high loads placed through the proximal femur, surgery is often indicated to provide pain relief and restore function. Historically, these lesions are reconstructed with a hemiarthroplasty; however, there are few reports on the outcome of these reconstructions. The purpose of this study is to evaluate the outcome of hemiarthroplasty for the treatment of proximal femur metastatic disease, with a specific focus on the rates of conversion to total hip arthroplasty (THA).
METHODS: One hundred ninety-nine patients (102 women, 97 men) were treated using a hemiarthroplasty to reconstruct the proximal femur for metastatic disease between 1992 and 2014. Mean age and body mass index were 62 years and 27.4 kg/m2, respectively. The most common site of primary disease was the breast (n = 63). The most common location for the metastatic disease was the femoral neck (n = 148). Mean follow-up for surviving patients was 4 years.
RESULTS: Over the course of the study, 2 (1%) patients underwent conversion to a THA due to groin pain and degenerative changes. In addition, complications occurred in 12% of patients, most commonly a deep venous thrombosis (n = 5). Following the procedure, mean Harris Hip Score and Musculoskeletal Tumor Society 1993 scores were 73 and 63%, respectively.
CONCLUSION: Reconstruction of the proximal femur with a hemiarthroplasty endoprosthesis provides a majority of patients with a durable means of reconstruction, with a low rate of conversion to THA.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  endoprosthesis; hemiarthroplasty; metastatic disease; outcome; proximal femur

Mesh:

Year:  2017        PMID: 28735800     DOI: 10.1016/j.arth.2017.06.040

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  7 in total

1.  How Often Do Acetabular Erosions Occur After Bipolar Hip Endoprostheses in Patients With Malignant Tumors and Are Erosions Associated With Outcomes Scores?

Authors:  Matthew T Houdek; Peter S Rose; Peter C Ferguson; Franklin H Sim; Anthony M Griffin; Mario Hevesi; Jay S Wunder
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

2.  Application of Endoprosthetic Replacement in Old Patients with Isolated Proximal Femoral Bone Metastases.

Authors:  Peng Liu; Zhuan Wang; Shiyuan Zhang; Guoqiang Ding; Ke Tan; Ji Zhou
Journal:  Ann Surg Oncol       Date:  2022-05-23       Impact factor: 5.344

3.  Surgical Management and Outcomes following Pathologic Hip Fracture-Results from a Propensity Matching Analysis of the Registry for Geriatric Trauma of the German Trauma Society.

Authors:  Christopher Bliemel; Katherine Rascher; Ludwig Oberkircher; Torsten Schlosshauer; Carsten Schoeneberg; Matthias Knobe; Bastian Pass; Steffen Ruchholtz; Antonio Klasan
Journal:  Medicina (Kaunas)       Date:  2022-06-29       Impact factor: 2.948

4.  [Perioperative clinical characteristics of patients with pathological fracture of proximal femur].

Authors:  Y P Cui; C Mi; B Wang; Y X Pa; Y F Lin; X D Shi
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

Review 5.  Advances in tumour endoprostheses: a systematic review.

Authors:  Maria A Smolle; Dimosthenis Andreou; Per-Ulf Tunn; Andreas Leithner
Journal:  EFORT Open Rev       Date:  2019-07-02

6.  Cemented vs uncemented megaprostheses in proximal femur metastases: a multicentric comparative study.

Authors:  Maria Serena Oliva; Francesco Muratori; Raffaele Vitiello; Antonio Ziranu; Lorenzo Foschi; Giuseppe Rovere; Cesare Meschini; Domenico Andrea Campanacci; Giulio Maccauro
Journal:  BMC Musculoskelet Disord       Date:  2022-09-06       Impact factor: 2.562

Review 7.  Application of three-dimensional printing technology in peripheral hip diseases.

Authors:  Shuai Liang; Jia Xie; Fangyuan Wang; Juehua Jing; Jun Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.